INT200802

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.61
First Reported 2006
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 2.86
Pain Relevance 0.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Jak2) cytosol (Jak2) signal transduction (Jak2)
histone binding (Jak2) cytoskeleton (Jak2) nucleus (Jak2)
Anatomy Link Frequency
megakaryocytes 1
Jak2 (Mus musculus)
Jak2 - V617F (1)
Pain Link Frequency Relevance Heat
fibrosis 20 95.36 Very High Very High Very High
cytokine 4 82.80 Quite High
Parenteral administration 2 26.24 Quite Low
Pain 6 6.40 Low Low
Paracetamol 8 5.00 Very Low Very Low Very Low
Bioavailability 7 5.00 Very Low Very Low Very Low
cva 5 5.00 Very Low Very Low Very Low
corticosteroid 4 5.00 Very Low Very Low Very Low
aspirin 4 5.00 Very Low Very Low Very Low
Potency 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myeloproliferative Disorder 40 99.92 Very High Very High Very High
Myeloid Leukemia 203 99.80 Very High Very High Very High
Myelodysplastic Syndromes 187 99.46 Very High Very High Very High
Hyperplasia 6 98.08 Very High Very High Very High
Disease 74 97.76 Very High Very High Very High
Leukemia 37 97.40 Very High Very High Very High
Fibrosis 16 95.36 Very High Very High Very High
Cancer 19 90.44 High High
Apoptosis 4 88.16 High High
Erythrocytosis 66 86.92 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Imatinib therapy can reduce the hematocrit in some human PV patients, but has minimal effects on the level of JAK2 V617F [31].
Regulation (effects) of JAK2 V617F (V617F) associated with myelodysplastic syndromes
1) Confidence 0.61 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762384 Disease Relevance 0.38 Pain Relevance 0
Typically, mice which receive the JAK2V617F BMT sequentially develop myeloid and erythroid hypercellularity, increased numbers of megakaryocytes and reticulin fibrosis.
Regulation (receive) of JAK2V617F in megakaryocytes associated with fibrosis and hyperplasia
2) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2749451 Disease Relevance 0.87 Pain Relevance 0.12
Targeting the JAK2V617F mutation and associated signal transduction pathways
Regulation (Targeting) of JAK2V617F
3) Confidence 0.26 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721304 Disease Relevance 0.49 Pain Relevance 0.04
One major effect of the JAK2 activation by Bcr-Abl is the increase in c-Myc expression (Xie et al 2002) which is important for leukemia induction (Sawyers et al 1992).
Regulation (effect) of JAK2 associated with leukemia
4) Confidence 0.20 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503652 Disease Relevance 0.52 Pain Relevance 0
Samanta et al (2006) identified JAK2 as a potentially important therapeutic target for CML.
Regulation (target) of JAK2 associated with myeloid leukemia
5) Confidence 0.12 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503652 Disease Relevance 0.60 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox